{"filings":[{"id":1110837,"accession_number":"0001453687-26-000090","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2026-06-17T20:01:15+00:00","items":["5.07"],"status":"ready","headline":"Cartesian Therapeutics shareholders elect three Class I directors, approve say-on-pay and auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Michael Singer, Timothy Springer, and Patrick Zenner elected Class I directors through 2029.","Non-binding advisory vote on named executive officer compensation approved (13.7M for, 136K against).","Ratification of Ernst & Young as independent auditor for FY2026 approved (24.1M for).","Approximately 82.42% of outstanding shares represented at June 12, 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":927518,"accession_number":"0001140361-26-024556","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2026-06-09T11:16:42+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cartesian licenses WestGene's in vivo CAR-T LNP platform for autoimmune diseases; MG trial starts 2H2026","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["WestGene receives upfront payment and milestone-based payments; Cartesian gains exclusive rights to WestGene's tLNP platform for in vivo CAR-T.","Phase 1 dose-escalation study of Descartes-08 mRNA delivered via WestGene's tLNPs in generalized myasthenia gravis expected to begin 2H 2026.","In-human proof-of-concept data expected in 1H 2027; Cartesian plans to advance additional anti-BCMA CAR constructs and a BCMA TCE.","WestGene's prior clinical data showed no DLTs, SAEs, ICANS, or IRRs in up to 14 doses per patient; only Grade 1 CRS observed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":649157,"accession_number":"0001453687-26-000087","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2026-05-26T11:08:51+00:00","items":["1.01","2.03","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Cartesian secures up to $150M debt facility; CMO resigns; Phase 3 data expected Q1 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Secured up to $150M credit facility with K2 HealthVentures; initial $50M tranche funded at close on May 22, 2026.","Term loans bear interest at 8.95% or prime+2.20% (whichever greater); matures June 1, 2030 with monthly amortization from July 2029.","CMO Milos Miljkovic resigns effective May 31, 2026; will receive severance including six months' salary and COBRA coverage.","Phase 3 AURORA topline data for Descartes-08 in myasthenia gravis expected in Q1 2027; BLA filing planned for mid-2027.","Cash runway extended into 2028; Phase 2 TRITON and Phase 1/2 HELIOS data expected in H1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92940,"accession_number":"0001453687-26-000081","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cartesian Q1 net loss $39.2M ($1.46/sh) vs $17.7M; cash $120.4M; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss widened to $39.2M from $17.7M YoY; higher R&D spend on Phase 3 AURORA trial.","Cash, equivalents & restricted cash $120.4M as of March 31; raised $14.6M via ATM in Q1.","Phase 3 AURORA trial enrollment continues; Phase 2 TRITON in myositis initiated; HELIOS pediatric trial progress.","R&D expenses $19.5M (up 33% YoY) due to AURORA; G&A $7.1M (down 14% YoY).","Cash runway expected into mid-2027, supporting completion of Phase 3 AURORA trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":78000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104188,"accession_number":"0001453687-26-000068","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cartesian Therapeutics board member Murat Kalayoglu resigns effective March 31, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Murat Kalayoglu, M.D., Ph.D. resigned from board effective March 31, 2026 to pursue other opportunities.","He served as Chairman of Science and Technology Committee and on Nominating and Corporate Governance Committee.","Resignation not due to any disagreement with the company on operations, policies, or practices.","Kalayoglu had been on board since 2023; no replacement announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104187,"accession_number":"0001453687-26-000063","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cartesian Therapeutics reports FY2025 net loss of $130.3M; cash $126.9M funds into mid-2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $130.3M ($5.02 per basic share) compared to $77.4M ($4.48) in FY2024.","R&D expenses rose to $58.0M from $45.1M, driven by Phase 3 AURORA trial and headcount growth.","Cash, equivalents and restricted cash of $126.9M expected to support operations into mid-2027, including AURORA completion.","Phase 3 AURORA trial for Descartes-08 in myasthenia gravis on track to enroll ~100 patients; Phase 2 TRITON in myositis IND accepted, initiation expected 1H26.","Board changes: Adrian Bot appointed in Dec 2025; Carsten Brunn named Chairman in Oct 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104186,"accession_number":"0001453687-26-000051","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cartesian updates Descartes-08 pipeline; IND accepted in myositis, pediatric trial initiated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 AURORA trial for Descartes-08 in myasthenia gravis enrollment on track; data expected to support cash runway into mid-2027.","FDA accepted IND for Descartes-08 in myositis; seamless adaptive Phase 2 TRITON trial expected to start 1H26.","Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis initiated.","Two Nature Medicine publications; Phase 2b MG data showed 55% median prednisone dose reduction at Month 12, no CRS or ICANS.","Cash resources expected to fund operations including Phase 3 trial completion through mid-2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120478,"accession_number":"0001453687-25-000140","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.02","5.05","7.02","7.01","9.01"],"status":"ready","headline":"Cartesian Therapeutics appoints Adrian Bot to board; brings CAR T and RNA therapy expertise","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Adrian Bot, M.D., Ph.D., as Class II director effective Dec 16, 2025; will serve on Science and Technology Committee.","Bot brings three decades of R&D experience in CAR T, cell/gene therapy and nanomedicines; former CSO of Capstan Therapeutics.","Initial compensation includes option for 17,200 shares at $8.29 and RSUs for 5,800 shares, with multi-year vesting schedules.","CEO highlights Bot's role in first-in-class CAR T therapies and Capstan's acquisition by Abbvie, relevant to Cartesian's autoimmunity focus.","Company is a clinical-stage biotech advancing cell therapy for autoimmune diseases; expects a critical year of execution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120477,"accession_number":"0001453687-25-000123","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cartesian reports 100% LLDAS response in Phase 2 SLE; expands Descartes-08 into myositis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% LLDAS response at Month 3 (n=3) in Phase 2 SLE trial; 2 of 3 achieved DORIS remission.","No CRS or ICANS observed; outpatient administration without lymphodepleting chemotherapy.","Plans to pause SLE and Descartes-15 (multiple myeloma) to prioritize MG Phase 3 and myositis.","Myositis seamless adaptive Phase 2 trial expected to start 1H26; IND filing by end 2025.","Cash runway extended to mid-2027 supporting MG Phase 3 and myositis trial initiation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120476,"accession_number":"0001453687-25-000119","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cartesian Q3 net loss $35.9M; cash $145.1M; AURORA trial on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $35.9M ($1.38/share) vs $24.2M ($1.13/share) in Q3 2024.","Cash, equivalents and restricted cash $145.1M, expected to fund ops into mid-2027.","Phase 3 AURORA enrollment on track; ~100 participants, primary endpoint at Month 4.","Preliminary Phase 2 SLE data and pediatric basket trial initiation expected by end of 2025.","R&D expense $13.8M (+21% YoY) due to AURORA trial and headcount growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":1850000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120475,"accession_number":"0001140361-25-039793","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["5.02","5.03","7.01","9.01"],"status":"ready","headline":"Cartesian Therapeutics Chair Carrie Cox resigns; CEO Carsten Brunn named Chairman, bylaw amended","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carrie Cox resigned from the Board and as Chair on Oct. 29, 2025, to focus on other commitments; not related to any disagreement.","Carsten Brunn, Ph.D., CEO and Board member, appointed Chairman of the Board effective immediately.","Patrick Zenner named Lead Independent Director; Kemal Malik appointed Chairman of the Compensation Committee.","Board approved amended and restated Bylaws to incorporate references to Lead Independent Director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120474,"accession_number":"0001453687-25-000106","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cartesian Therapeutics eliminates CSO role, terminates Dr. Christopher Jewell effective Nov 14, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CSO position eliminated; Dr. Christopher Jewell terminated without cause effective November 14, 2025.","Separation agreement signed Oct 20, 2025 provides 12 months salary and pro-rated bonus eligibility.","Dr. Jewell releases all claims against the company in exchange for severance benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120473,"accession_number":"0001453687-25-000104","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cartesian Therapeutics appoints June Seymour as Chief Accounting Officer effective Oct 27, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annual base salary of $385,000; eligible for annual performance bonus targeted at 35% of base salary.","Receives $80,000 sign-on bonus and option to purchase 50,000 shares vesting over four years.","Ms. Seymour most recently served as SVP, Finance and Accounting at DNAnexus; previously VP Finance at Neogene Therapeutics.","CFO Blaine Davis continues as both principal financial officer and principal accounting officer.","Employment agreement includes six-month severance (base salary and pro-rata bonus) and 12-month non-compete."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137045,"accession_number":"0001453687-25-000098","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cartesian Therapeutics reports Q2 net income $15.9M; initiates Phase 3 AURORA trial for Descartes-08 in MG","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and restricted cash $162.1M as of June 30, 2025; expected to fund operations into mid-2027.","Net income $15.9M ($0.51 basic EPS) vs $13.8M ($0.58 basic EPS) in Q2 2024.","R&D expenses $14.9M, up from $12.7M, driven by Phase 3 AURORA trial costs.","Preliminary Phase 2 data for Descartes-08 in SLE expected in 2H25; pediatric basket trial initiation also expected in 2H25.","Phase 3 AURORA trial of Descartes-08 in myasthenia gravis dosed first participant in May 2025; primary endpoint at Month 4."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":1398000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154318,"accession_number":"0001453687-25-000093","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cartesian Therapeutics stockholders elect three Class III directors and approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["84.31% of outstanding shares represented; each director nominee elected with votes for >19.2M.","Non-binding advisory say-on-pay approved: 19.7M for, 157k against, 2.0M broker non-votes.","Ratification of Ernst & Young as independent auditor for FY2025 approved: 21.8M for, 6k against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154317,"accession_number":"0001453687-25-000091","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cartesian Therapeutics enrolls first patient in Phase 3 AURORA trial of Descartes-08 for myasthenia gravis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First participant enrolled in randomized, placebo-controlled Phase 3 AURORA trial of Descartes-08 (CAR-T) in ~100 patients with AChR Ab+ myasthenia gravis.","Descartes-08 is administered outpatient without preconditioning chemotherapy; primary endpoint is proportion with MG-ADL improvement ≥3 points at Month 4.","Phase 2b data cited: average 4.8-point MG-ADL reduction at Month 12; in biologic-naive subgroup 7.1-point reduction and 57% minimal symptom expression.","Safety profile consistent with prior data; continues to support outpatient administration without integrating vectors or conditioning chemotherapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154316,"accession_number":"0001453687-25-000084","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cartesian Therapeutics Q1 net loss $17.7M; cash $182.1M; Phase 3 AURORA on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.7M ($0.68 basic loss per share) vs $56.8M ($10.50) in Q1 2024; R&D expenses rose to $14.7M.","Cash, equivalents and restricted cash $182.1M as of March 31, 2025; expected to fund operations into mid-2027.","Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) expected to begin in Q2 2025 with ~100 participants.","Phase 2b data showed sustained MG-ADL reduction of 4.8 points at Month 12; deeper 7.1-point drop in biologic-naïve subgroup.","Preliminary Phase 2 SLE data and Phase 2 pediatric basket trial initiation expected in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":1100000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154315,"accession_number":"0001453687-25-000077","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cartesian Therapeutics CTO Metin Kurtoglu to depart May 1; will serve as consultant through April 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CTO Metin Kurtoglu's employment ends May 1, 2025; consulting agreement runs through April 30, 2026.","Separation agreement includes 12 months salary, pro-rated bonus eligibility, and accelerated vesting of equity awards granted Jan 2, 2024.","Release of claims upon receipt of severance benefits as per employment agreement dated March 28, 2024.","No replacement named; Dr. Kurtoglu will remain in advisory role under consulting terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154314,"accession_number":"0001453687-25-000064","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cartesian reports Descartes-08 Phase 2b MG data: sustained 12-month benefit, Phase 3 on track","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Average MG-ADL reduction of 4.8 points at Month 12; 83% maintained clinically meaningful response.","In biologic-naive subgroup (n=7): avg 7.1-point MG-ADL reduction, 57% achieved minimum symptom expression (MG-ADL 0-1) at Month 12.","No new safety signals; no CRS or ICANS; supports outpatient administration without lymphodepleting chemo.","Phase 3 AURORA trial on track to dose first patient in Q2 2025; FDA SPA agreement for trial design."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172901,"accession_number":"0001453687-25-000059","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cartesian Therapeutics FY2024 net loss $77.4M; cash $214.3M; Phase 3 MG trial on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $77.4M ($4.48 loss per share) vs $219.7M loss in FY2023; R&D expenses $45.1M.","Cash, equivalents and restricted cash $214.3M at Dec 31, 2024; expected to fund operations into mid-2027.","Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track for 1H25; FDA SPA agreement secured.","Preliminary Phase 2 SLE data expected 2H25; Phase 2 pediatric basket trial to initiate 2H25 in select autoimmune indications.","Dosing ongoing in first-in-human Phase 1 trial of Descartes-15 for multiple myeloma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172900,"accession_number":"0001453687-25-000054","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cartesian Therapeutics files 8-K with corporate slide deck; no material news evident","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Slide deck titled 'Pioneering mRNA Cell Therapy for Autoimmunity' dated March 2025 furnished as Exhibit 99.1.","No financial results, pipeline updates, or guidance changes provided in the filing.","The exhibit is furnished under Regulation FD and contains no new material information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172899,"accession_number":"0001453687-25-000050","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cartesian Therapeutics receives FDA SPA agreement for Phase 3 AURORA trial of Descartes-08 in MG","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agrees under Special Protocol Assessment that Phase 3 AURORA trial design can support future BLA for Descartes-08 in myasthenia gravis.","Phase 3 trial expected to start in first half of 2025; randomized, placebo-controlled, 100 AChR Ab+ participants.","Primary endpoint: proportion with ≥3-point MG-ADL improvement at Month 4 vs placebo; 1:1 randomization.","Phase 2b data showed average MG-ADL reduction of 5.5 (±1.1) at Month 4 (n=12); well-tolerated without preconditioning chemo.","SPA provides regulatory clarity and a clear path toward potential approval of Descartes-08."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172898,"accession_number":"0001453687-25-000043","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cartesian Therapeutics outlines 2025 priorities; Phase 3 MG trial to start in 1H25","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track for 1H25; primary endpoint is MG-ADL improvement ≥3 points at Month 4 vs placebo.","Update Phase 2b MG data: average MG-ADL reduction of 5.5 at Month 4 (n=12); deepening responses over time; no need for preconditioning chemo.","Phase 2 SLE trial of Descartes-08 enrolling; data readout expected in 2H25. SLE affects ~1.5M people in the US.","Descartes-15 Phase 1 dose escalation ongoing in multiple myeloma; after Phase 1, will assess in autoimmune indications.","Cash runway expected to support operations, including completion of Phase 3 MG trial, into mid-2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189916,"accession_number":"0001453687-24-000143","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cartesian announces positive updated Phase 2b data for Descartes-08 in MG; Phase 3 AURORA on track for H1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Descartes-08 showed 5.5-point average MG-ADL reduction at Month 4 (n=12); 33% reached minimum symptom expression at Month 6.","Responses durable through Month 12: 80% (4/5) maintained clinically meaningful improvement.","No CRS or ICANS reported; safety supports outpatient administration without lymphodepleting chemo.","Phase 3 AURORA trial (n≈100) to begin H1 2025; primary endpoint: ≥3-point MG-ADL improvement vs placebo at Month 4.","Retreated Phase 2a patients showed rapid responses again; no new safety signals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189915,"accession_number":"0001453687-24-000122","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cartesian Q3 net loss $(24.2)M; cash $220.9M; Phase 3 Descartes-08 in MG expected 1H2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $220.9M as of Sep 30, 2024; runway expected into mid-2027.","Net loss $(24.2)M ($(1.13)/share) vs $(9.0)M ($(1.74)) in Q3 2023.","Research and development expenses $11.4M, down from $13.0M year-over-year.","Plan to commence Phase 3 trial of Descartes-08 in myasthenia gravis in 1H2025 after FDA meeting.","Completed $130M PIPE financing in July 2024; first patient dosed in Phase 2 SLE trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":39672000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206427,"accession_number":"0001453687-24-000110","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cartesian Therapeutics completes automatic conversion of Series B Preferred Stock; 23.9M common shares outstanding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders at Sept 20 special meeting approved issuance of common shares from Series B Preferred Stock conversion.","Automatic conversion of all Series B Non-Voting Convertible Preferred Stock completed on Sept 25, 2024.","Following conversion, there are 23,893,525 shares of common stock issued and outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206426,"accession_number":"0001453687-24-000108","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stockholders approve conversion of Series B Preferred at special meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Special meeting held Sep 20, 2024; 75.9% of outstanding shares represented.","Proposal 1 passed: 12,514,261 FOR, 150,060 AGAINST, 1,650 abstentions (excluding 3,563,247 shares for Nasdaq compliance).","Proposal 2 (adjournment if needed) approved: 16,076,183 FOR, 151,789 AGAINST, 1,246 abstentions.","Approval allows issuance of common stock upon conversion of Series B Non-Voting Convertible Preferred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206425,"accession_number":"0001453687-24-000100","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cartesian reports positive Phase 2b MG data, Q2 net income $13.8M, $130M PIPE","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 2b trial of Descartes-08 in MG met primary endpoint: 71% (10/14) of treated patients vs 25% (3/12) placebo had ≥5-point MGC improvement at Month 3 (p=0.018).","Q2 2024 net income of $13.8M ($0.58/share) vs net loss of $11.4M ($2.23/share) in Q2 2023; revenue included $30M milestone from Sobi.","Completed $130M PIPE financing in July 2024; cash and equivalents $88.9M at June 30, 2024, expected to fund Phase 3 MG trial and early commercial prep.","Dosed first SLE patient in Phase 2 trial; IND filing for pediatric basket study expected by year-end 2024; Descartes-15 Phase 1 expected H2 2024.","Appointed Dr. Kemal Malik to board; End-of-Phase 2 FDA meeting expected by year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":39285000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206424,"accession_number":"0001140361-24-032080","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["1.01","5.03","3.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Cartesian raises $130M via PIPE; Phase 2b MG trial meets primary endpoint, 71% responder rate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$130M by selling 3.56M common shares and 2.94M Series B convertible preferred shares at $20 each.","Phase 2b trial of Descartes-08 in myasthenia gravis met primary endpoint: 71% of treated patients had ≥5-point MGC improvement vs 25% placebo (p=0.018).","Descartes-08 well tolerated with no cytokine release syndrome or neurotoxicity; supports outpatient administration without preconditioning chemo.","Appointed Kemal Malik, MBBS to Board; first patient dosed in Phase 2 SLE trial of Descartes-08."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223572,"accession_number":"0001453687-24-000088","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Cartesian stockholders elect directors, approve incentive plan, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Carrie S. Cox (11.8M for) and Murat Kalayoglu (12.1M for) elected to Class II board until 2027.","Stockholders approved amended & restated 2016 Incentive Award Plan (11.3M for, 857K against).","Non-binding advisory vote on executive compensation passed (11.7M for, 444K against).","Ernst & Young ratified as independent auditor for 2024 (13.5M for, 212K against).","Annual meeting turnout: 13.8M shares voted, ~77.3% of outstanding common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223571,"accession_number":"0001453687-24-000084","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cartesian Therapeutics receives FDA RMAT designation for Descartes-08 in myasthenia gravis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted RMAT designation for Descartes-08, an autologous mRNA CAR-T therapy targeting BCMA for myasthenia gravis.","RMAT designation provides fast track and breakthrough therapy benefits, enabling expedited FDA interactions and development.","Topline data from Phase 2b randomized, double-blind, placebo-controlled trial of Descartes-08 in MG expected mid-2024.","Descartes-08 previously received FDA Orphan Drug Designation for MG.","Phase 2a data (Jan 2024) showed durable autoantibody depletion and clinically meaningful MG severity score improvements over 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223570,"accession_number":"0001453687-24-000081","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cartesian Q1 2024 net loss $56.8M; cash $104.8M; MG Phase 2b data on track for mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $56.8M ($10.50/shr) vs $21.7M ($4.24/shr) Q1 2023; loss widened on higher G&A from merger.","Cash, equivalents, restricted cash $104.8M; expected to fund operations into 2H 2026.","R&D expenses $9.7M (down from $18.6M) on pipeline reprioritization; G&A $9.5M (up from $5.7M) on merger costs.","Phase 2b topline for Descartes-08 in myasthenia gravis expected mid-2024; SLE Phase 2 dosing starts Q2 2024.","Completed 1-for-30 reverse stock split and preferred conversion; new Maryland HQ expanding manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":-10.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":5840000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223569,"accession_number":"0001453687-24-000072","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cartesian regains Nasdaq minimum bid price compliance; delisting risk removed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received deficiency notice Jan 17, 2024 for bid price below $1.00 for 30 consecutive days.","Compliance period granted until July 15, 2024 to cure the deficiency.","On April 19, 2024, Nasdaq confirmed bid price ≥ $1.00 for 10 consecutive days from April 5-18.","Nasdaq considers the matter closed; company remains listed on Nasdaq Global Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223568,"accession_number":"0001453687-24-000055","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cartesian Therapeutics Series A Preferred automatically converts, resulting in 17.8M shares outstanding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Automatic conversion of Series A Non-Voting Convertible Preferred Stock occurred on April 8, 2024.","After conversion, common stock outstanding totals 17,779,787 shares.","No further Series A Preferred shares remain outstanding; previously approved by stockholders on March 27, 2024.","Company also filed updated corporate slide presentation for investor conferences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223567,"accession_number":"0001453687-24-000052","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cartesian Therapeutics enters employment pacts with CSO Jewell ($420K) and CTO Kurtoglu ($440K)","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Jewell appointed CSO; annual base salary $420,000, target bonus 40%.","Metin Kurtoglu appointed CTO (was COO); annual base salary $440,000, target bonus 40%.","Severance: 12 months base pay, prorated bonus, and COBRA if terminated without cause or for good reason.","Change-in-control provision: accelerated vesting of time-based equity awards if termination occurs near a change.","Both executives subject to 12-18 month non-compete, non-solicit, and confidentiality covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243002,"accession_number":"0001453687-24-000048","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["5.03","5.07","7.01","8.01","9.01"],"status":"ready","headline":"Cartesian stockholders approve Series A conversion and 1-for-30 reverse split effective April 4","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved issuance of common shares upon conversion of Series A Non-Voting Convertible Preferred Stock; automatic conversion set for April 8, 2024.","Approved 1-for-30 reverse stock split effective after market close on April 4, 2024; trading on split-adjusted basis begins April 5 under RNAC.","Post-split shares outstanding will drop from ~165.5M to ~5.5M (before conversion) or ~17.8M (after conversion of most preferred shares).","No fractional shares; cash payment in lieu will be made; ~166.3K preferred shares remain subject to beneficial ownership limits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243001,"accession_number":"0001453687-24-000039","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Cartesian Therapeutics announces termination of license agreement with Astellas for Xork in Pompe disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Astellas terminated the License and Development Agreement effective June 6, 2024, for Xork product candidate.","Agreement provided exclusive license for Xork in combination with Astellas' gene therapy for Pompe disease.","Cartesian had received $10M upfront and was eligible for up to $340M in milestones and royalties; no early termination penalties.","After termination, Cartesian has no further financial commitments or liabilities related to Xork.","Future milestone and royalty payments from the deal are forfeited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243000,"accession_number":"0001453687-24-000035","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cartesian Therapeutics FY2023 net loss $219.7M; cash runway into 2H26","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Pro forma cash $118.3M as of Dec 31, 2023, expected to fund operations into 2H26.","Net loss of $219.7M ($1.66/share) vs net income of $35.4M ($0.24/share) in FY2022.","R&D expenses $71.8M, G&A $40.6M; G&A rose $16.7M on merger costs.","Topline Phase 2b data for Descartes-08 in MG expected mid-2024; Phase 2 SLE study to start 1H24.","Special stockholder meeting March 27, 2024 to vote on preferred conversion and 1:20-1:30 reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242999,"accession_number":"0001140361-24-011282","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Cartesian leases 20K sq ft cGMP facility in Frederick, MD; director resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Leased ~20,000 sq ft manufacturing/office space at 7495 New Horizon Way, Frederick, MD.","Initial term from April 2024 to May 2031 (7 years) with one 5-year extension option.","Base rent $902,353/year ($47/sq ft) with 3% annual escalation.","Director Aymeric Sallin resigned from board effective immediately, not due to disagreement.","Facility to support cGMP manufacturing for autoimmune disease pipeline; Phase 2b Descartes-08 data due mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242996,"accession_number":"0001140361-24-003407","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K/A","filed_at":"2024-01-23T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Cartesian Therapeutics files financials for acquired Old Cartesian and pro forma","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Old Cartesian net loss $6.5M in 2022, vs $3.6M in 2021; grant revenue $1.4M in 2022.","Old Cartesian cash $12.0M at Dec 31, 2022; accumulated deficit $26.1M.","Unaudited pro forma financials reflect combined entity post-merger closed Nov 13, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242998,"accession_number":"0001453687-24-000030","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Cartesian Therapeutics receives Nasdaq notice of non-compliance with minimum bid price requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Cartesian on Jan 17, 2024 that its common stock closing bid price fell below $1.00 for 30 consecutive business days.","Company has until July 15, 2024 to regain compliance; must close at or above $1.00 for 10 consecutive business days.","If not compliant by July 15, may qualify for additional 180-day period by transferring to Nasdaq Capital Market and meeting other standards.","Cartesian intends to monitor bid price and consider available options; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242997,"accession_number":"0001140361-24-001205","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cartesian reports positive 12-month Phase 2a data for Descartes-08 in MG; cash $118M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["12-month follow-up: 5 of 7 Phase 2a MG patients maintained clinically meaningful improvements ~10 months after last infusion; autoantibodies durably reduced.","Descartes-08 well-tolerated with no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity; outpatient administration without lymphodepletion.","Phase 2b topline data expected mid-2024; Phase 2 study in SLE to initiate 1H24; IND cleared for next-gen Descartes-15 for multiple myeloma.","Pro forma cash ~$118M as of Dec 31, 2023; expected to fund operations into 2H 2026, through Phase 3 of Descartes-08.","Common shares outstanding: 161.9M; Series A preferred convertible into ~534.3M common shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260391,"accession_number":"0001453687-23-000091","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2023-11-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cartesian Therapeutics board member Scott D. Myers resigns effective Nov 21, 2023; not due to disagreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott D. Myers resigned from the Board of Directors effective November 21, 2023.","Resignation was to pursue other opportunities and not due to any disagreement with the Company.","Myers also ceased service on the Compensation and Nominating and Corporate Governance Committees.","The Company thanked Myers for his service since joining the board in June 2019.","No replacement was announced; ticker RNAC listed on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260393,"accession_number":"0001193125-23-275461","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["1.01","5.03","2.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Selecta completes merger with Cartesian; renamed Cartesian Therapeutics, ticker RNAC","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed Nov 13; Selecta issued 6.7M common shares and 384,931 Series A Preferred to Cartesian holders.","Insider PIPE of $60.25M from board member Springer and former CEO Kalayoglu trust; 149,330 Series A Preferred sold.","New officers appointed: Metin Kurtoglu (COO), Milos Miljkovic (CMO), Chris Jewell (CSO); former CMO/CSO/COO resigned.","CVRs to be issued to Selecta stockholders, entitling them to 100% of future Sobi license milestones/royalties.","Series A Preferred convertible into 1,000 common shares each, subject to stockholder approval of charter amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260392,"accession_number":"0001453687-23-000070","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"Selecta transitions SEL-212 manufacturing to Sobi; CMO goes part-time","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Selecta granted Sobi exclusive license to manufacture ImmTOR for SEL-212; Sobi assumes all manufacturing and commercial supply.","15 Selecta employees expected to become Sobi employees; CMO Peter Traber moves to part-time at Selecta and consultant to Sobi.","Selecta retains eligibility for up to $615M in remaining milestones and tiered double-digit royalties on SEL-212 net sales.","BLA submission for SEL-212 on track for first half of 2024; peak U.S. sales potential estimated at >$700M.","Dr. Traber's base salary reduced to $250,000; severance benefits tied to pre-amendment salary in certain termination scenarios."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277685,"accession_number":"0001453687-23-000064","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2023-09-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Selecta Biosciences approves retention bonuses for five executives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Carsten Brunn (CEO) and Blaine Davis each receive 2x annual salary bonus; Peter Traber 1.5x; Takashi Kei Kishimoto 1x; Lloyd Johnston 2x.","Bonus payable on first payroll after March 31, 2024 if executive remains employed in good standing.","Compensation Committee may accelerate payment or waive service requirements at its discretion.","Retention bonuses aim to incentivize key leadership continuity through March 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277684,"accession_number":"0001453687-23-000061","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2023-09-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Selecta Biosciences fully repays debt under loan agreement with Oxford Finance and Silicon Valley Bank","summary_kind":"llm","event_type":"debt","confidence":"low","bullets":["Paid all outstanding amounts under Loan and Security Agreement dated Aug 31, 2020 (as amended).","Accrued interest and prepayment penalty included; all obligations discharged in full.","All unfunded commitments terminated; liens and security interests automatically released.","Warrants previously issued to Oxford and Silicon Valley Bank remain outstanding.","No financial amounts disclosed; company no longer has debt obligations under this agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277683,"accession_number":"0001193125-23-214706","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2023-08-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Selecta posts Q2 net loss of $11.4M; suspends pipeline investment to focus on SEL-212 BLA filing in 1H 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $11.4M ($0.07/share) vs net income of $8.6M ($0.06) in Q2 2022; collaboration revenue fell to $5.2M from $39.3M.","Cash, equivalents, restricted cash, marketable securities $115.0M as of June 30, 2023; expected to fund operations into 2027.","BLA submission for SEL-212 (chronic refractory gout) on track for 1H 2024; eligible for up to $615M in remaining milestone payments from Sobi.","Halting further investment in pipeline assets including ImmTOR-IL; evaluating licensing/corporate development for pipeline programs.","Partnership with Astellas for Xork IgG protease in LOPD continues; Xork designed to expand gene therapy access."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295661,"accession_number":"0001453687-23-000059","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Selecta Biosciences annual meeting: three directors elected; charter amendment to lower vote threshold fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected Scott D. Myers, Timothy A. Springer, and Patrick Zenner as Class I directors for three-year terms.","Advisory vote on executive compensation passed with approx. 91% of votes cast in favor (63.7M for, 5.1M against, 1.1M abstain).","Proposal to amend certificate of incorporation to change bylaw amendment threshold from two-thirds to majority failed, receiving less than two-thirds of outstanding shares.","Ratification of Ernst & Young as auditor for FY2023 was approved with overwhelming support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295660,"accession_number":"0001453687-23-000043","cik":1453687,"company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","form_type":"8-K","filed_at":"2023-04-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Selecta Biosciences amends loan agreement, eases SVB collateral account requirement","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Fourth Amendment to Loan and Security Agreement dated March 31, 2023 with Oxford Finance and SVB (First-Citizens).","Relaxes Section 6.6: must hold lesser of 100% consolidated cash or 150% outstanding obligations in SVB collateral accounts.","Borrower released all claims against lenders arising from loan documents.","Updates references to SVB to reflect its acquisition by First-Citizens Bank & Trust Company.","No Event of Default exists after amendment; representations and warranties reaffirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":206552035.2842713,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-04-04T23:59:59+00:00|295660"}